Elutia(ELUT)
SILVER SPRING, MDBiotechnology
Focus: Elutia is a public biotechnology company specializing in drug-eluting biomatrix technologies for cardiovascular, oncology, and other therapeutic areas. The company operates at a modest commercial scale with $14M in FY2025 revenue.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Elutia
AI assessmentNot HiringNo open roles listed right now. Follow Elutia to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Elutia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
14 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$14M
Pipeline & Clinical Trials
CanGaroo
Heart DiseasesClinical Trials (1)
NCT04299282CIED Implantation in Low BMI Patients
N/AHelp build intelligence for Elutia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.